<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0">
    <channel>
        <image>
            <title>freepatentsonline.com</title>
            <width>141</width>
            <height>131</height>
            <link>http://www.freepatentsonline.com/</link>
            <url>http://www.freepatentsonline.com/images/logo.gif</url>
        </image>
        
        <title>Free Patents Online: Chemistry: molecular biology and microbiology</title>
        <link>http://www.freepatentsonline.com/rssfeed/rssapp435.xml</link>
        <description>USPTO Class 435 Chemistry: molecular biology and microbiology</description>
        <language>en-us</language>
        <lastBuildDate>Thu, 13 Jun 2013 08:00:00 EDT</lastBuildDate>
        <item>
            <title><![CDATA[Polypeptides Having Lipase Activity And Polynucleotides Encoding Same]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152234.html</link>
            <description><![CDATA[The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods for Agrobacterium-Mediated Transformation of Sugar Cane]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152232.html</link>
            <description><![CDATA[The present invention provides methods for Agrobacterium-mediated transformation of sugar cane (Saccharum spp.) comprising introducing a nucleotide sequence of interest into a sugar cane callus tissue or cell thereof via Agrobacterium mediated delivery, wherein the sugar cane callus tissue is less than 28 days post-initiation. The invention further provides methods for transforming a sugar cane callus tissue or cell thereof comprising inoculating the sugar cane callus tissue that is less than 28 days post-initiation with an Agrobacterium comprising a nucleotide sequence of interest to produce an Agrobacterium-inoculated sugar cane tissue or cell thereof; and co-cultivating the Agrobacterium and the sugar cane callus tissue to produce a transformed sugar cane callus tissue or cell thereof.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[FUNCTIONAL EXPRESSION OF YEAST NITRATE TRANSPORTER (YNT1) IN MAIZE TO IMPROVE NITRATE UPTAKE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152231.html</link>
            <description><![CDATA[The present invention provides methods and compositions relating to altering NT activity, nitrogen utilization and/or uptake in plants. The invention relates to a method for the production of plants with maintained or increased yield under low or normal nitrogen fertility. The invention provides isolated nitrate transporter (NT) nucleic acids and their encoded proteins. The invention further provides recombinant expression cassettes, host cells, and transgenic plants. Plants transformed with nucleotide sequences encoding the NT enzyme show improved properties, for example, increased yield.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[GENES ENCODING A NOVEL TYPE OF LYSOPHOPHATIDYLCHOLINE ACYLTRANSFERASES AND THEIR USE TO INCREASE TRIACYLGLYCEROL PRODUCTION AND/OR MODIFY FATTY ACID COMPOSITION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152230.html</link>
            <description><![CDATA[Described nucleic acid molecules (and corresponding peptides) encode lyso-phosphatidylcholine (LPC) acyltransferases. Over-expression of the LPC acyltransferases in a cell may lead to enhanced production of PUFA, or other unusual fatty acids, and/or to increased oil content in the cell.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MARCHANTIALES-DERIVED UNSATURATED FATTY ACID SYNTHETASE GENES AND USE OF THE SAME]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152229.html</link>
            <description><![CDATA[A Δ5 fatty acid desaturase gene, a Δ6 fatty acid desaturase gene, and a Δ6 fatty-acid-chain elongase gene are isolated from a single species of Marchantiales. By introducing these genes into higher plants, transformed plants which can produce arachidonic acid and eicosapentaenoic acid (EPA) are obtained.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Method of Increasing Resistance Against Fungal Infection in Transgenic Plants by HCP-2-Gene]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152228.html</link>
            <description><![CDATA[The present invention relates to a method of increasing resistance against fungal infection in transgenic plants and/or plant cells. In these plants, the content and/or the activity of a HCP-2-protein are increased in comparison to the wild-type plants not including a recombinant HCP-2-gene.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[ENHANCED DISEASE RESISTANCE BY INTRODUCTION OF NH3]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152227.html</link>
            <description><![CDATA[Methods and compositions for improving plant resistance by expression of NPR homolog 3 (NH3) polypeptides are provided.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITIONS AND METHODS FOR MODIFYING GENE EXPRESSION USING THE PROMOTER OF UBIQUITIN CONJUGATING PROTEIN CODING GENE OF SOYBEAN PLANTS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152226.html</link>
            <description><![CDATA[A polynucleotide isolated from soybean plants capable of initiating transcription and with sequence identity to SEQ ID No. 1 is provided. In some aspects, the polynucleotide has sequence identity to SEQ ID No. 1 of at least 40%, is the reverse complement or the reverse of such sequences. In some aspects, the polynucleotide is linked to expression enhancers or sequences of interest. In some embodiments, a recombinant vector comprises the polynucleotide. In some aspects, the recombinant vector comprises enhancers, termination sequences, or sequences of interest. In some embodiments a transformed cell, plant, plant part, or propagulum comprise the polynucleotide.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Plant Stress Tolerance Related Protein TaDREB4B and Encoding Gene and Use Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152225.html</link>
            <description><![CDATA[Provided are a plant stress tolerance related protein TaDREB4B and encoding gene and use thereof. The TaDREB4B protein has the amino acid sequence as shown in SEQ ID NO. 1, which can be expressed under induction by drought, high salt, high temperature, low temperature, pathogenic bacteria, ABA, ethylene, JA and SA, and can specially regulate the transcriptional expression of gene comprising the DRE/CRT cis element (core sequence: CCGAC), thereby enhancing the drought resistance, salt tolerance, high temperature tolerance and resistance to pathogenic bacteria of powdery mildew of plant.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Genes and uses for plant improvement]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152224.html</link>
            <description><![CDATA[Transgenic seed for crops with improved traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more improved traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Dual Purpose Pollenizer Watermelons]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152223.html</link>
            <description><![CDATA[The application relates to the field of plant breeding, in particular watermelon breeding. Provided are diploid watermelon plants (and seeds from which these plants can be grown) which produce small, diploid, red watermelon fruits. Also provided are small, diploid watermelon fruits having an average weight of less than 1.8 kg.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[TRANSGENIC FISH AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0152222.html</link>
            <description><![CDATA[The present invention relates to a transgenic fish having at least one genomically integrated expression cassette containing a 5′-regulatory nucleotide sequence responsive to hormones, particularly estrogenic hormones, connected in a functional manner upstream of a nucleotide sequence encoding a reporter protein. The present invention further relates to methods of using the transgenic fish for various purposes, including, for example: (1) identifying estrogenic endocrine disruptors; (2) monitoring estrogen-like activity of test samples; (3) identifying anti-estrogenic endocrine disruptors; and (4) investigating the effects of endocrine disruptors on liver regeneration. Expression cassettes, host cells, and transgenic cells of aquatic animals are also disclosed.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[BIODEGRADABLE POLYURETHANE/UREA COMPOSITIONS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150964.html</link>
            <description><![CDATA[The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[SYSTEM AND METHOD FOR SORTING CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150663.html</link>
            <description><![CDATA[Improved flow cytometer system particularly adapted to use for sex-selected sperm sorting include enhanced sheath fluid and other strategies which minimize stress on the sperm cells, including a 2.9 percent sodium citrate sheath solution for bovine species and a hepes bovine gamete media for equine species. Improved collection systems and techniques for the process are described so that commercial applications of sperms samples as well as the resulting animals may be achieved.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Production of High Levels of DHA in Microalgae Using Modified Amounts of Chloride and Potassium]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150604.html</link>
            <description><![CDATA[Methods for production of highly unsaturated fatty acids by marine microorganisms, including the heterotrophic marine dinoflagellate Crypthecodinium, using low levels of chloride ion are disclosed. Specifically, methods of increasing production of highly unsaturated fatty acids by marine microorganisms while growing in low chloride media by manipulating sodium ion and potassium ion levels. The invention also relates to methods of production of highly unsaturated fatty acids by marine organisms at low pH levels, and includes methods for generation of low pH tolerant strains.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Production of DHA and Other LC-PUFAs in Plants]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150599.html</link>
            <description><![CDATA[The invention provides recombinant host organisms (e.g., plants) genetically modified with a polyunsaturated fatty acid (PUFA) synthase system and one or more accessory proteins (e.g., PPTase and/or ACoAS) that allow for and/or improve the production of PUFAs in the host organism. The present invention also relates to methods of making and using such organisms (e.g., to obtain PUFAs) as well as products obtained from such organisms (e.g., oil and/or seed).]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[TUMOR-TARGETED TNF-RELATED APOPTOSIS-INDUCING LIGAND'S VARIANT AND THE APPLICATION THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150566.html</link>
            <description><![CDATA[The invention belongs to the field of genetic engineering and biotechnology, and specifically discloses a design, preparation and pharmic application of a tumor-targeted TNF-related apoptosis-inducing ligand's variant. The tumor-targeted TNF-related apoptosis-inducing ligand's variant is generated by a fused protein which is consisted of the ligand of CD13, the connecting peptide and TNF-related apoptosis-inducing ligand's variant, and which is by the construction of coding gene of the variant according to the technology of genetic engineering and clone, soluble recombinant expression and ordinary separation and purification. The variant, produced by the method of preparation of the tumor-targeted TNF-related apoptosis-inducing ligand's variant, has favorable tumor-targeting characteristics and the significant enhancement of the anti-tumor effect. It is possible to reducing the required dosage of protein to the treatment effect, increasing the bioavailability, reducing the cost of treatment and overcome the potential toxic effects of the TNF-realated apoptosis-inducing ligand. Moreover, the preparation method of the tumor targeted TNF-related apoptosis-inducing ligand's variant of the present invention provides a method for producing the variant of soluble expression and high concern of polymer forms and a process of separation and purification thereof.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[NOVEL COLLECTIN]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150565.html</link>
            <description><![CDATA[Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[AMYLOID BETA-DERIVED DIFFUSIBLE LIGANDS (ADDLs), ADDL-SURROGATES, ADDL-BINDING MOLECULES, AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150560.html</link>
            <description><![CDATA[The invention herein comprises amyloid beta-derived diffusible ligands (ADDLs), compositions comprising ADDLs, ADDL-surrogates, ADDL-binding molecules, and methods of using any of the foregoing compounds and compositions. ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of generating ADDL-specific antibodies and methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[CELL CULTURE OF GROWTH FACTOR-FREE ADAPTED CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150554.html</link>
            <description><![CDATA[The present invention provides improved cell culture systems that allow optimum production of recombinant proteins. Among other things, the present invention provides methods of cell culture including a step of cultivating cells adapted to growth factor-free medium in a cell culture system that provides at least one growth factor.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PIG MODEL FOR BREAST CANCER, MITOCHONDRIA RELATED PROTEIN FOLDING DISORDERS AND/OR EPIDERMOLYSIS BULLOSA SIMPLEX]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150465.html</link>
            <description><![CDATA[The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods for Impairing the P53/HDM2 Auto-Regulatory Loop in Multiple Myeloma Development Using mIR-192, mIR-194 and mIR-215]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150430.html</link>
            <description><![CDATA[Methods and compositions for detecting, treating, characterizing, and diagnosing multiple myeloma are described.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[P27KIP1 AS A MOLECULAR MARKER FOR SUITABILITY AND EFFICACY OF TREATMENT WITH HSP27 INHIBITORS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150429.html</link>
            <description><![CDATA[Cells expressingHsp27 exhibit reduced levels of p27kip1. Accordingly, a method for treatment of cancer using hsp27 inhibition that includes a preliminary test to ascertain the status of the p27kip1 in the target cells. In this test, a sample of cancerous tissue from the patient from the patient (including a human patient) and evaluated to determine an expression of level of functional p27kip1. In the case where the expression level of p27kip1 is below a threshold level, a therapeutic composition comprising as an active agent a composition effective to inhibit the expression or activity of hsp27 in administered to the patient.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[REGULATION OF METABOLISM BY MIR-378]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150427.html</link>
            <description><![CDATA[The present invention provides a method of regulating fatty acid metabolism in a cell by contacting the cell with a modulator of miR-378 and/or miR-378* activity or expression. The present invention also provides a method of treating or preventing a metabolic disorder, such as obesity, diabetes, or metabolic syndrome, in a subject by administering to the subject an inhibitor of miR-378 and/or miR-378* expression or activity. Methods of treating or preventing pathologic cardiac hypertrophy, cardiac remodeling, myocardial infarction, or heart failure in a subject by inhibiting the expression or activity of miR-378 and/or miR-378* in a subject are also disclosed.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[SUBSTITUTED AMINO-QUINAZOLINONES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150387.html</link>
            <description><![CDATA[The present invention relates to substituted amino-quinazolinones of general formula (I) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PYRAZOLOQUINOLINES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150359.html</link>
            <description><![CDATA[The invention relates to compounds of the formulae (I), (II) and (III), and/or physiologically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formula (II) or (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of its salts]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[THERAMUTEIN MODULATORS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150358.html</link>
            <description><![CDATA[This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150345.html</link>
            <description><![CDATA[A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: one of R3 and R4 is H, and the other is selected from C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoxy, and C6-12-aralkyl;or R3 and R4 are each independently selected from C1-6-alkyl and halo;R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high efficacies for human cathepsin S, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, Sjogrens syndrome, Grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods For Reducing Superoxide Anions in Eukaryotic Organisms]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150336.html</link>
            <description><![CDATA[Provided are methods and compositions for reducing superoxide anions such that a prophylactic or therapeutic effect against conditions associated with excess oxidative stress achieved. The compositions and methods provide for reducing inflammation and for enhancing lifespan of eukaryotic organisms. A screen for identifying compounds that can be used in these methods is also provided.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[LEVOCARRIMYCIN, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150316.html</link>
            <description><![CDATA[The present invention relates to levocarrimycin, its pharmaceutical compositions, preparation methods and application. Levocarrimycin is a mixture of isovalerylspiramycin III, II and I as main components and contains some isobutyrylspiramycin III and II, butyrylspiramycin III and II, propionylspiramycin III and II, as well as acetylspiramycin III and II, among which, the content of isovalerylspiramycin III is no less than 30 wt %, the total content of isovalerylspiramycin III, II and I is no less than 60 wt %, and the content of acylspiramycin is 80-98 wt %. Specific optical rotation of said levocarrimycin is [α]D=−52°˜−57° in the solution of 0.02 g/ml chloroform at temperature of 25° C. The present invention also relates to the crystalline compound of isovalerylspiramycin III, II or I in levocarrimycin, and pharmaceutical compositions containing the said levocarrimycin. In present invention, the active components in levocarrimycin or its pharmaceutical compositions have optical activity and excellent anti-infective effect.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[VH4 CODON SIGNATURE FOR MULTIPLE SCLEROSIS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150308.html</link>
            <description><![CDATA[The present invention provides for the diagnosis and prediction of multiple sclerosis (MS) in subject utilizing a unique a codon signature in VH4 expressiong B cells that has now been associated with MS and not with any other autoimmune disease.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[GLYCOSAMINOGLYCAN-ANTAGONISING MCP-1 MUTANTS AND METHODS OF USING SAME]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150303.html</link>
            <description><![CDATA[Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[SPECIFIC BINDING SITES IN COLLAGEN FOR INTEGRINS AND USE THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150300.html</link>
            <description><![CDATA[The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Na+/K+-ATPase-Specific Peptide Inhibitors/Activators of Src and Src Family Kinases]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150294.html</link>
            <description><![CDATA[A method for regulating Src and its downstream signaling pathway which includes binding between Src and Na+/K+-ATPase is disclosed. The Na+/K+-ATPase/Src complex is a functional receptor for cardiotonic steroids such as ouabain. Also disclosed are Src inhibitors or activators which include either Na+/K+-ATPase or Src that interfere with the interaction between the Na/K-ATPase and Src, act via a different mechanism from ATP analogues, and is pathway (Na+/K+-ATPase) specific.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150293.html</link>
            <description><![CDATA[The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Soft Protease Inhibitors and Pro-Soft Forms Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150292.html</link>
            <description><![CDATA[The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[SHORT PEPTIDES USEFUL FOR TREATMENT OF ISCHEMIA/REPERFUSION INJURY AND OTHER TISSUE DAMAGE CONDITIONS ASSOCIATED WITH NITRIC OXIDE AND ITS REACTIVE SPECIES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150283.html</link>
            <description><![CDATA[This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH; SEQ ID NOS: 1 and 15) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury and other disorders.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[HUMAN T2R NUCLEIC ACID SEQUENCES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150263.html</link>
            <description><![CDATA[Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Method and Kit for Identifying Compounds Capable of Inhibiting Human Papilloma Virus Replication]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150262.html</link>
            <description><![CDATA[This invention provides a method, kit and an in vitro system for identifying compounds capable of inhibiting Human Papilloma Virus replication at all the stages of viral replication cycle. The method, kit and in vitro system is applicable to all types of Human Papilloma Virus. The method enables high throughput screening of compounds inhibiting HPV replication in one or more phases of the cycle.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS AND COMPOSITIONS FOR SAMPLE IDENTIFICATION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150257.html</link>
            <description><![CDATA[Compositions and methods are provided to provide an expression signature for a sample, where an alternative splicing index and profile are determined for the sample based on variations in the splicing of messenger RNA for at least one gene in the sample.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[NOVEL MICRORNAS FOR THE DETECTION AND ISOLATION OF HUMAN EMBRYONIC STEM CELL-DERIVED CARDIAC CELL TYPES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150256.html</link>
            <description><![CDATA[The present invention relates to the use of human-derived microRNAs (miRNAs) as targets for the identification of cardiac and cardiac-like cell types. In particular, it relates to a specific set of miRNAs which have been found to be correlated to cardiac differentiation and can act to up or downregulate a number of putative mRNA targets to guide differentiation and also act as markers for a cardiac phenotype. In addition, it also relates to the use of these miRNAs as tools for the isolation, selection, purification and characterisation of cardiac and cardiac-like cells and tissues. The invention also encompasses the possible use of these miRNAs in the differentiation and maturation of cardiac or cardiac-like cell types.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Reagents and methods for direct labeling of nucleotides]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150254.html</link>
            <description><![CDATA[The present invention provides systems and methods for production of activatable diazo-derivatives for use in labeling nucleotides. Labeling nucleotides is accomplished by contacting a stable hydrazide derivative of a detectable moiety with an activating polymer reagent which is used to directly label the nucleotide sample. Labeling occurs on the phosphate backbone of the nucleotide which does not perturb hybridization of the labeled nucleotide with its anti-sense strand. Since the method involves direct labeling, all types of nucleotides can be labeled without prior amplification or alteration.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[DETECTION AND MEASUREMENT OF TISSUE-INFILTRATING LYMPHOCYTES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150252.html</link>
            <description><![CDATA[The present invention is drawn to methods for measuring numbers, levels, and/or ratios of cells, such as lymphocytes, infiltrated into a solid tissue, such as a tumor or a tissue affected by an autoimmune disease, and to methods for making patient prognoses based on such measurements. In one aspect, methods of the invention comprise sorting lymphocytes from an accessible tissue, such as peripheral blood, into functional subsets, such as cytotoxic T cells and regulatory T cells, and generating clonotype profiles of each subset. An inaccessible disease-affected tissue is sampled and one or more clonotype profiles are generated. From the latter clonotype profiles, levels lymphocytes in each of the functional subsets are determined in the disease-affected tissue by their clonotypes, which are identified from lymphocytes sorted into subsets from the accessible tissue.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR ANALYZING LARIAT RNA]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150251.html</link>
            <description><![CDATA[The present invention relates to compositions and methods useful for analyzing lariat RNA, which plays a role in the regulation of gene expression. A sample of RNA is specifically treated to remove linear mRNA and enrich for lariat RNA. The enriched lariat RNA sample may be analyzed further to identify introns, branch point sequences, alternative splicing patters, and gene transcription levels. The enriched lariat RNA sample may also be exploited as a detection or compound screening tool, as well as other uses.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESSES AND COMPOSITIONS FOR METHYLATION-BASED ENRICHMENT OF FETAL NUCLEIC ACID FROM A MATERNAL SAMPLE USEFUL FOR NON-INVASIVE PRENATAL DIAGNOSES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0150249.html</link>
            <description><![CDATA[Provided are compositions and processes that utilize genomic regions differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuplodies.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[I-CREI VARIANTS WITH NEW SPECIFICITY AND METHODS OF THEIR GENERATION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149786.html</link>
            <description><![CDATA[The present invention relates to 1-Cre1 variants which can in particular recognise and cleave DNA targets which do not comprise the same nucleotides at positions ±6 and ±7 which are present in the wild type 1-Cre1 target. The present invention also relates to 1-Cre1 variants which can recognise and cleave targets which do not comprise the wild type nucleotides at positions ±4, ±5, ±6, ±7 and to 1-Cre1 variants with new specificity which can recognise and cleave targets which do not comprise the wild type nucleotides at positions ±4, ±5, ±6, ±7, ±8, ±9 and ±10.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR MAKING AND USING MOLECULAR SWITCHES INVOLVING CIRCULAR PERMUTATION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149785.html</link>
            <description><![CDATA[The invention provides molecular switches which couple external signals to functionality, and combinatorial methods of making and using the same involving circular permutation of nucleic acid and amino acid sequences. The switches according to the invention can be used, for example, to regulate gene transcription, target drug delivery to specific cells, transport drugs intracellularly, control drug release, provide conditionally active proteins, perform metabolic engineering, and modulate cell signaling pathways. Libraries comprising the switches, expression vectors and host cells for expressing the switches are also provided.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD OF IN-VITRO FERTILIZATION WITH SPERMATOZOA SEPARATED INTO X-CHROMOSOME AND Y-CHROMOSOME BEARING POPULATIONS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149784.html</link>
            <description><![CDATA[An IVF system for successfully utilizing spermatozoa separated into X-chromosome bearing and into Y-chromosome bearing population for insemination. The IVF system includes fertilization medium that can shorten the time from insemination to cleavage and a portable incubator for the transportation of maturing oocytes and inseminated oocytes comprising a straw (19) and an incubation element (20) that can be sealed with a cap (22).]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[CLEAVABLE MODIFICATIONS TO REDUCIBLE POLY (AMIDO ETHYLENIMINES)S TO ENHANCE NUCLEOTIDE DELIVERY]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149783.html</link>
            <description><![CDATA[Polyplex formulations were prepared using p(TETA/CBA), its PEGylated analog, p(TETA/CBA)-g-PEG2k, and mixtures of the two species at 10/90 and 50/50 wt %, respectively. Increasing PEG wt % inhibited polyplex formation. This work demonstrates the feasibility of preparing homogenous polyplexes by altering the PEG wt % using a mixture of p(TETA/CBA) and p(TETA/CBA)-g-PEG2k products. Further, a single-step method of making p(TETA/CBA)-g-PEG2k is disclosed.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Thermally Induced Gelation Of Collagen Hydrogel And Method Of Thermally Inducing Gelling A Collagen Hydrogel]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149782.html</link>
            <description><![CDATA[The present invention relates to collagen hydrogels. Particularly, the invention relates to hydrogels comprising a telopeptide collagen (“telo-collagen”) and an atelopeptide collagen (“atelo-collagen”); hydrogels comprising collagen and chitosan; methods of making the hydrogels; methods of reducing gelation of a hydrogel mixture at room temperature; methods of reducing compaction of cells; and methods of culturing cells on such hydrogels.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Nucleotide-Specific Recognition Sequences For Designer TAL Effectors]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149781.html</link>
            <description><![CDATA[The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Nucleotide-Specific Recognition Sequences For Designer TAL Effectors]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149780.html</link>
            <description><![CDATA[The invention relates to methods of altering expression of a genomic locus of interest or specifically targeting a genomic locus of interest in an animal cell, which may involve contacting the genomic locus with a non-naturally occurring or engineered composition that includes a deoxyribonucleic acid (DNA) binding polypeptide having a N-terminal capping region, a DNA binding domain comprising at least five or more Transcription activator-like effector (TALE) monomers and at least one or more half-monomers specifically ordered to target the genomic locus of interest, and a C-terminal capping region, wherein the polypeptide includes at least one or more effector domains, and wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide preferentially binds to the DNA of the genomic locus.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[COMBINATIONS OF PROTEINS TO ENHANCE VIABILITY OF STEM CELLS AND THEIR PROGENITORS BEFORE TRANSPLANTATION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149779.html</link>
            <description><![CDATA[Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human α1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Method and Applications of Peptide-Mediated Mitochondrial Delivery System]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149778.html</link>
            <description><![CDATA[The present invention relates to a method using a cell penetrating peptide (Pep-1) for labeling and delivering mitochondria separated from healthy cells to replace damaged mitochondria. At present, microinjection of mitochondria into cells can only process one cell at a time, and therefore, this technique is limited to embryo related research and relevant applications. The advantages of the said peptide-mediated mitochondrial delivery system (PMD) include less steps with more efficiency, where a number of cells can be treated following one labeling process; the delivery process can be easily controlled, there is no cell toxicity after delivery under appropriate conditions, and delivery efficiency is over 80% depending on different cell types. Mitochondria delivered by the PMD system will move to the original mitochondrial location in the cells and will not be catalyzed in lysosomes; thus, the therapeutic effects can last at least one week.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Magnetically Coupled System For Mixing]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149777.html</link>
            <description><![CDATA[The invention provides a mixing system comprising a magnetically coupled drive system and a foil for cultivating algae, or cyanobacteria, in an open or enclosed vessel. The invention provides effective mixing, low energy usage, low capital expenditure, and ease of drive system component maintenance while maintaining the integrity of a sealed mixing vessel.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Assay Devices and Methods]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149776.html</link>
            <description><![CDATA[A device for determining an assay result may include a test strip, a light source system, a light detection system, and a processor.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[DEVICE FOR RAPID DETECTION OF INFECTIOUS AGENTS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149775.html</link>
            <description><![CDATA[A portable system for real time detection of the presence of an infectious agent in a biological sample employs a reagent which detects the presence of a specific infectious agent in the sample, and emits a detectable signal when the reagent reacts with the sample and detects the presence of the infectious agent. A test cartridge has a reaction chamber for receiving the sample and the reagent. The reaction chamber has a predetermined internal geometry and at least one inner surface. Introducing the sample and the reagent into the test cartridge mixes the sample and the reagent. A testing unit receives the test cartridge, and includes a sensor for detecting an emitted detectable signal. The detection of the emitted detectable signal is indicative of the presence of the infectious agent in the sample.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[COLLECTIVE CELL COUNTER SYSTEM]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149774.html</link>
            <description><![CDATA[A cell counter system includes an inlet via which a fluid containing a plurality of cells inflows; a channel in which the fluid flows; a valve unit, which controls flow of the fluid in the channel; an electrode unit, which is arranged in the channel for measuring impedance for counting a number of the plurality of cells; and an outlet, which is connected to the channel to drain the fluid.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Bacteria Cultures and Compositions Comprising Bacteria Cultures]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149773.html</link>
            <description><![CDATA[The present invention relates to bacteria cultures and composition comprising one or more cultures of the invention. The invention also relates to methods of washing or cleaning laundry or fabrics and surfaces as well as degrading waste material using a bacteria culture of the invention.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MAGNETIC ION-EXCHANGE RESIN AND METHOD FOR THE PREPARATION THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149772.html</link>
            <description><![CDATA[Magnetic ion-exchange polymer microspheres and a method for preparing the same are provided. The method for preparing the magnetic ion-exchange polymer microspheres includes swelling the ion-exchange resins and allowing the magnetic nano-particles to enter the interior of the ion-exchange resins. The magnetic ion-exchange resins of the present invention have various functional groups can be introduced onto the surfaces thereof. Therefore, the magnetic ion-exchange resins of the present invention can be applied in many areas, and thereby they have high economic value.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Heat-Stable Persephonella Carbonic Anhydrases and Their Use]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149771.html</link>
            <description><![CDATA[The present invention relates to use of Persephonella carbonic anhydrase in CO2 extraction, e.g., from flue gas, natural gas, biogas or ambient air. The Persephonella carbonic anhydrases are especially well suited for these purpose due to their extreme thermostability.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Variant Alpha-Amylases from Bacillus Subtilis and Methods of Uses, Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149770.html</link>
            <description><![CDATA[Alpha-amylases from Bacillus subtilis (AmyE), variants thereof, nucleic acids encoding the same, and host cells comprising the nucleic acids are provided. Methods of using AmyE or variants thereof are disclosed, including liquefaction and/or saccharification of starch. Such methods may yield sugars useful for ethanol production or high fructose corn syrup production. In some cases, the amylases can be used at low pH, in the absence of calcium, and/or in the absence of a glucoamylase.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[NOVEL CARBONYL REDUCTASE, GENE THEREFOR AND USE THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149769.html</link>
            <description><![CDATA[The present invention is to provide a process for efficiently producing an optically active alcohol including (R)-3-hydroxy-3-phenylpropanenitrile. One of the features of the present invention is a polypeptide having an activity of asymmetrically reducing 3-oxo-3-phenylpropanenitrile isolated from a microorganism belonging to the genus Candida to product (R)-3-hydroxy-3-phenylpropanenitrile, DNA encoding the polypeptide and a transformant of producing the polypeptide. Another feature of the present invention is a process for producing an optically active alcohol such as (R)-3-hydroxy-3-phenylpropanenitrile by reducing a carbonyl compound such as 3-oxo-3-phenylpropanenitrile by use of the polypeptide or the transformant.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[CATALYST FUNCTIONALIZED BUFFER SORBENT PEBBLES FOR RAPID SEPARATION OF CARBON DIOXIDE FROM GAS MIXTURES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149768.html</link>
            <description><![CDATA[A method for separating CO2 from gas mixtures uses a slurried media impregnated with buffer compounds and coating the solid media with a catalyst or enzyme that promotes the transformation of CO2 to carbonic acid. Buffer sorbent pebbles with a catalyst or enzyme coating are provided for rapid separation of CO2 from gas mixtures.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS FOR THE CONVERSION OF CARBON-BASED MATERIAL BY A HYBRID ROUTE COMBINING DIRECT LIQUEFACTION AND INDIRECT LIQUEFACTION IN THE PRESENCE OF HYDROGEN RESULTING FROM NON-FOSSIL RESOURCES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149767.html</link>
            <description><![CDATA[A process for the conversion of carbon-based material to fuel bases by a hybrid route combining direct ebullent bed liquefaction and indirect liquefaction by gasification followed by a Fischer-Tropsch synthesis, including a stage of production of hydrogen resulting from non-fossil resources and a reverse water gas reaction stage. This process makes it possible to limit emissions of greenhouse gases.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PRODUCTION OF BIO-BASED MATERIALS USING PHOTOBIOREACTORS WITH BINARY CULTURES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149766.html</link>
            <description><![CDATA[A method, device and system for producing preselected products, (either finished products or preselected intermediary products) from biobased precursors. The principal features of the present invention include a method wherein a binary culture is incubated with a biobased precursor in a closed system to transform at least a portion of the biobased precursor to a preselected product. This improvement leads to significant savings in energy consumption and allows for the design of photobioreactors of any desired shape. The present invention also allows for the use of a variety of types of waste materials to be used as the organic starting material.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[ANAEROBIC DIGESTER FOR THE PRODUCTION OF METHANE GAS FROM ORGANIC WASTE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149765.html</link>
            <description><![CDATA[An anaerobic digester to produce methane gas from animal manure. The anaerobic digester preferably includes a reactor vessel with a solar concentrator and an RF emitter. The reactor vessel may be loaded from the top with animal manure, sealed and evacuated during which the waste may be subject to focused light energy and/or subject to RF Energy from the RF emitter in order to facilitate anaerobic digestion, and then cleaned out with an auger turning out the resultant waste solids. An enzyme catalyst may also be employed to further facilitate anaerobic digestion. Methane gas produced as a result of anaerobic digestion is pumped from the reactor vessel and collected for further processing and/or burned for energy and/or heat.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS AND SYSTEM FOR PRODUCING ETHANOL FROM A BYPRODUCT OF AN ETHANOL PRODUCTION FACILITY]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149764.html</link>
            <description><![CDATA[A process of producing ethanol from whole stillage, includes obtaining a supply of whole stillage from an ethanol production facility after ethanol has been extracted therefrom; pre-treating the whole stillage to convert hemicellulose portions of the whole stillage into sugars; adding enzymes to the whole stillage to convert cellulose portions of the whole stillage to sugars; fermenting the whole stillage to create a beer mixture; and distilling the beer mixture to separate ethanol therefrom. The pre-treating step may include adding acid to the whole stillage to decrease its pH level; heating and pressurizing the whole stillage; holding the whole stillage under pressure and heat for a dwell time; removing pressure from the whole stillage to cause flashing; and cooling the whole stillage before the enzymes are added.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS AND SYSTEM FOR PRODUCING ETHANOL FROM A BYPRODUCT OF AN ETHANOL PRODUCTION FACILITY]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149763.html</link>
            <description><![CDATA[A process of producing ethanol from whole stillage, includes obtaining a supply of whole stillage from an ethanol production facility after ethanol has been extracted therefrom; pre-treating the whole stillage to convert hemicellulose portions of the whole stillage into sugars; adding enzymes to the whole stillage to convert cellulose portions of the whole stillage to sugars; fermenting the whole stillage to create a beer mixture; and distilling the beer mixture to separate ethanol therefrom. The pre-treating step may include adding acid to the whole stillage to decrease its pH level; heating and pressurizing the whole stillage; holding the whole stillage under pressure and heat for a dwell time; removing pressure from the whole stillage to cause flashing; and cooling the whole stillage before the enzymes are added.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Processes of Producing Fermentation Products]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149762.html</link>
            <description><![CDATA[The invention relates to a process of fermenting plant material in a fermentation medium into a fermentation product using a fermenting organism, wherein one or more carbonic anhydrases are present in the fermentation medium.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD TO RECOVER SUGARS OF PRE-TREATED LIGNOCELLULOSIC BIOMASS LIQUIDS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149761.html</link>
            <description><![CDATA[This specification discloses a process for the removal of solids and non-sugar components from a pre-treated lignocellulosic biomass stream by the precipitation of the non-sugar components with preferably barium hydroxide or calcium hydroxide. The precipitation removes the non-sugar components and some salts, leaving the glucose and xylose and other sugars in the liquid stream for further processing.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[New Yeast Strains for Improved Ethanol Production]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149760.html</link>
            <description><![CDATA[Novel strains of yeast and methods for improved ethanol production utilizing the yeast strains are disclosed. In particular, the novel yeast strains Saccharomyces cerevisae YE1358 and YE1615 provide for increased fermentation temperature tolerance, as well as tolerance to increased levels of glucose and ethanol, and thereby provide increased ethanol production as compared to ethanol industry standard strains of Saccharomyces cerevisae. The novel yeast strains also generate decreased residual glucose than the ethanol industry standard yeasts.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Application of Bacteriophages for the Control of Unwanted Bacteria in Biofuel Production Mediated by Bacterial Reactive Agents]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149759.html</link>
            <description><![CDATA[A method of reducing process interruptions in biofuel production systems mediated by bacterial reactive agents by reducing the amount of unwanted bacteria without reduction of wanted or useful bacteria. The method comprises applying a phage panel(s) containing phage virulent for unwanted bacteria that does not contain phage phages virulent wanted bacteria. The method includes, optionally, the selective production of solutions of phage for unwanted bacteria from which phages for wanted bacteria are screened out.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Conversion System For Biomass]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149758.html</link>
            <description><![CDATA[The efficient production of ethanol from low-cost biomass (e.g., corn, sugar beets, sugar cane, switchgrass and/or paper) has become increasingly important in making ethanol competitive with gasoline and decreasing the United States' dependence on foreign oil. For example, to reduce the cost of transporting biomass to ethanol production facilities, mobile systems for producing ethanol from biomass are provided. Also provided are small-scale ethanol production facilities. For example, instead of transporting biomass to the production facility, the facility is transported to the biomass or is located nearby the source of the biomass. The ethanol production facilities or components thereof may be transported via land, water, or air. Production of other products, such as hydrocarbons, natural gas, hydrogen gas, plastics, polymers, and proteins, can also be made by the methods and facilities. Any product described herein can be made in finished form or un-finished form and moved, e.g., to a fixed facility, e.g., fixed production facility.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Method for Producing Butanol and Isopropanol]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149757.html</link>
            <description><![CDATA[A novel Clostridium has been found that produces primarily n-butanol and isopropanol. Increased butanol was obtained by growing it continuously in an immobilized structure and extracting fermentation products immediately thereafter in a continuous flow extraction medium. Increased production was also achieved by fermentation in the presence of an extraction medium (such as corn oil) to decrease product inhibition followed by product separation from the fermentation broth and the extraction medium.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Whole-Cell Biotransformation Of Fatty Acids To Obtain Fatty Aldehydes Shortened By One Carbon Atom]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149756.html</link>
            <description><![CDATA[The present invention relates to the area of producing aliphatic aldehydes with 5 to 31 carbon atoms, in particular by microbial conversion of corresponding aliphatic fatty acids with 6 to 32 carbon atoms. The invention also relates to enzymes for catalysing a conversion reaction of this type and nucleic acids coding for this.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[USE OF OXYHYDROGEN MICROORGANISMS FOR NON-PHOTOSYNTHETIC CARBON CAPTURE AND CONVERSION OF INORGANIC AND/OR C1 CARBON SOURCES INTO USEFUL ORGANIC COMPOUNDS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149755.html</link>
            <description><![CDATA[Compositions and methods for a hybrid biological and chemical process that captures and converts carbon dioxide and/or other forms of inorganic carbon and/or CI carbon sources including but not limited to carbon monoxide, methane, methanol, formate, or formic acid, and/or mixtures containing CI chemicals including but not limited to various syngas compositions, into organic chemicals including bio-fuels or other valuable biomass, chemical, industrial, or pharmaceutical products are provided. The present invention, in certain embodiments, fixes inorganic carbon or CI carbon sources into longer carbon chain organic chemicals by utilizing microorganisms capable of performing the oxyhydrogen reaction and the autotrophic fixation of CO2 in one or more steps of the process.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Optimization of Lipid Synthesis and Accretion]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149754.html</link>
            <description><![CDATA[The present invention relates to a novel mutant strain of yeast, particularly a strain of Yarrowia lipolytica, which is capable of accumulating a large quantity of lipids. Said strain is deficient in the beta-oxidation of fatty acids and overexpresses the GPD1 gene. Preferably, the mutant strains, which do not express the GUT2 gene and which are deficient for the beta-oxidation of fatty acids, do not express the POX2 to POX5 genes, very preferably the POX2 to 6 genes. The invention also relates to a method for obtaining the strains of yeast according to the invention and to the use of said strains in the production of lipids.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Application of Bacteriophages for the Control of Unwanted Bacteria in Biofuel Production Mediated by Non-Bacterial Reactive Agents]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149753.html</link>
            <description><![CDATA[A method of reducing process interruptions in biofuel production systems by reducing the amount of unwanted bacteria in the biofuel production system in which the reduction is effected by the use of an effective amount of one or more types of bacteriophages virulent for at least some strains of the unwanted bacteria.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[(R)-HYDROXYNITRILE LYASE FROM BRASSICACEAE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149752.html</link>
            <description><![CDATA[The invention concerns a polypeptide which can be isolated from the Brassicaceae family and which has at least the activity of a hydroxynitrile lyase (HNL). The hydroxynitrile lyase of the invention is the first HNL from the Brassicaceae family. The plants (Arabidopsis) from which this enzyme or its gene is isolated is also described as non-cyanogenic. All HNL-containing plants described so far are cyanogenic plants and so it has until now been assumed that only cyanogenic plants contain hydroxynitrile lyases. Surprisingly, it transpires that a polypeptide (AtHNL) of the invention is (R)-selective. The amino acid sequence gives a theoretical molecular weight of 29.2 kDa for the AtHNL subunit. The calculated molecular mass of the protein of approximately 30 kDa can be confirmed by SDS gel electrophoresis.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS FOR PREPARING AMINOCYCLOHEXYL ETHER COMPOUNDS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149751.html</link>
            <description><![CDATA[The present invention relates to a process for preparing aminocyclohexyl ether compounds of Formula I: or the pharmaceutically acceptable salts and esters thereof. In particular, the instant invention is directed towards a process for preparing (1R,2R)-2-[(3R)-Hydroxypyrrolidinyl]-1-(3,4-dimethoxyphenethoxy)-cyclohexane as well as various intermediates.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR PRETREATMENT OF CELLULOSE FOR FERMENTATION IN AN AQUEOUS ENVIRONMENT]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149750.html</link>
            <description><![CDATA[A method for pretreating cellulose for fermentation in an aqueous environment comprises the steps of: grinding a biomass to reduce its particle size, adding water to the ground biomass to create a slurry, soaking the slurry, heating the slurry at a first pressure greater than atmospheric pressure, reducing the pressure of the slurry, reducing the temperature of the slurry, determining whether the enzymes used require preliminary enzymatic hydrolysis, and performing preliminary enzymatic hydrolysis on the slurry if the enzymes used require preliminary enzymatic hydrolysis.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[POLYMERASE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149749.html</link>
            <description><![CDATA[An engineered DNA polymerase characterised in that the polymerase exhibits an enhanced ability to process nucleic acid in the presence of environmental and biological inhibitors compared to wild type DNA polymerase.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[DNA POLYMERASES WITH IMPROVED ACTIVITY]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149748.html</link>
            <description><![CDATA[Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[DNA POLYMERASES WITH IMPROVED ACTIVITY]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149747.html</link>
            <description><![CDATA[Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[DEVICE AND METHOD OF AMPLIFYING NUCLEIC ACIDS BY USING OIL LAYER COMPRISING EXOTHERMAL PARTICLES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149746.html</link>
            <description><![CDATA[The disclosure describes example devices and methods for amplifying nucleic acids by using an oil layer including exothermal particles, forming an emulsion using the oil layer including exothermal particles, and performing a nucleic acids amplification reaction in the emulsion. The nucleic acids amplification reaction may be effectively performed even with a small amount of a sample by maximizing nucleic acids amplification efficiency, reducing reaction time, and improving controls to be convenient.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR PRODUCING CHEMICALS BY CONTINUOUS FERMENTATION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149745.html</link>
            <description><![CDATA[A method produces a chemical by fermentation including: filtering a liquid containing a feedstock, the chemical, and bacterial, microbial or cultured cells through a membrane to recover the chemical from the filtrate; retaining or refluxing unfiltered liquid in the liquid; and adding the feedstock to the liquid, wherein the membrane is a porous hollow-fiber membrane including a polyvinylidene fluoride resin, the porous hollow-fiber membrane having an average pore size of 0.001 μm to 10.0 μm, pure water permeability coefficient at 50 kPa at 25° C. of 0.5 m3/m2/hr to 15 m3/m2/hr, breaking strength of 5 MPa to 20 MPa, elongation at break of 30% to 200%, crimping degree of 1.3 to 2.5, porosity of not less than 40%, and critical surface tension of 45 mN/m to 75 mN/m.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods for Producing a Fusion Protein Capable of Binding VEGF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149744.html</link>
            <description><![CDATA[The present invention provides methods for producing a fusion protein capable of binding vascular endothelial cell growth factor (VEGF). The methods of the invention comprise growing recombinant cells in suspension culture, wherein the recombinant cells contain an expression vector comprising a nucleic acid molecule encoding a fusion protein that binds VEGF, and isolating the fusion protein from the suspension culture. The fusion protein may comprise a VEGF receptor component having an immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR ENHANCING LUMINESCENCE INTENSITY OF CLYTIN-II]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149743.html</link>
            <description><![CDATA[A method for enhancing a luminescence activity of clytin-II is provided. A codon-optimized nucleic acid is used for coding the apo-clytin-II protein, and the luminescent activity of the clytin-II is remarkably enhanced when comparing with the conventional use of the wild-type clytin-II.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[FILAMENTOUS FUNGAL HOST STRAINS AND DNA CONSTRUCTS, AND METHODS OF USE THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149742.html</link>
            <description><![CDATA[The present disclosure relates to filamentous fungal host strains and recombinant DNA constructs for creation and use thereof. The filamentous fungal host strains are particularly useful for achieving reliable expression of recombinant enzymes and variants.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR IMPROVED PRODUCTION OF BIOACTIVE WNT PROTEINS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149741.html</link>
            <description><![CDATA[Methods and compositions for protein expression are provided. In particular, cells producing efficient and reliable amounts of functional Wnt protein are provided.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR THE PRODUCTION OF A POLYMERIZED PRODUCT]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149740.html</link>
            <description><![CDATA[The invention discloses a method for the production of a polymerized product comprising the following steps: providing a polymerization device to which a polymerization mixture and a separation medium can be applied and wherein flow of said mixture and medium can be conducted in appropriate ducts for said mixture and medium,transporting said polymerization mixture in a duct of said polymerization device thereby allowing the polymerization reaction,transporting said mixture in a duct of said polymerization device in a continuous flow,interrupting said continuous flow of said mixture with said separation medium so as to obtain consecutive volumes of said mixture and volumes of said separation medium,further transporting said consecutive volumes of said mixture and volumes of said separation medium in a duct of said polymerization device wherein said mixture further polymerizes to obtain a discontinuous polymerized product, and removing said discontinuous polymerized product from said polymerization device.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[DETECTION AND ENUMERATION OF MICROORGANISMS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149739.html</link>
            <description><![CDATA[A method for detecting and enumerating viable microorganisms in a sample suspected of containing said microorganisms: (1) contacting said microorganisms of said sample with repair compounds and a growth medium, and (2) incubating the product of step (1), and (3) detecting and enumerating said microorganisms, in which the microorganisms are of the species Legionella pneumophila, and in which the repair compounds comprise: (a) serine; (b) threonine; (c) a compound containing calcium ions at a dose of 10−6 to 10−2 mM; (d) a compound containing magnesium ions at a dose of 10−6 to 10−2 mM; (e) a compound containing potassium ions; (f) glutamic acid or a salt thereof; and (g) pyruvic acid or a salt thereof. The invention also discloses a kit for detecting and enumerating viable microorganisms of the species Legionella pneumophila in a sample suspected of containing said microorganisms.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MICROBIAL DETECTION SYSTEM AND METHODS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149738.html</link>
            <description><![CDATA[The disclosure provides culture devices and methods for a microorganism in a sample. The devices include a base member, a cover sheet, an adhesive layer coupled to the base member or the cover sheet, and a cold water-soluble gelling agent disposed on the base member; wherein the devices are substantially optically transmissive when the gelling agent is hydrated with a clear liquid. Methods of use include detecting or enumerating microorganisms. The methods further provide for detecting a microorganism by detecting the presence or size of an abiogenic gas bubble (540, 542) in a culture device.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[SYSTEM AND METHOD FOR SORTING CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149737.html</link>
            <description><![CDATA[Improved flow cytometer system particularly adapted to use for sex-selected sperm sorting include enhanced sheath fluid and other strategies which minimize stress on the sperm cells, including a 2.9 percent sodium citrate sheath solution for bovine species and a hepes bovine gamete media for equine species. Improved collection systems and techniques for the process are described so that commercial applications of sperms samples as well as the resulting animals may be achieved.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR SORTING PARTICLES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149736.html</link>
            <description><![CDATA[A multi-channel apparatus for classifying particles according to one or more particle characteristics. The apparatus comprises a plurality of flow cytometry units, each of which is operable to classify particles in a mixture of particles by interrogating a stream of fluid containing the particles with a beam of electromagnetic radiation. The flow cytometry units share an integrated platform comprising at least one of the following: (1) a common supply of particles; (2) a common housing; (3) a common processor for controlling operation of the units; (4) a common processor for receiving and processing information from the units; and (5) a common fluid delivery system. The integrated platform can include a common source of electromagnetic radiation. A method of the invention comprises using a plurality of flow cytometry units sharing the integrated platform to perform a flow kilometric operation, such as analyzing or sorting particles.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MICROFLUIDIC ASSAY IN IDEALIZED MICROVASCULAR NETWORK FOR CHARACTERIZATION OF LEUKOCYTE ADHESION CASCADE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149735.html</link>
            <description><![CDATA[Methods of assaying the leukocyte adhesion cascade (LAC) and monitoring leukocyte rolling, adhesion, and/or migration can be implemented with an apparatus that includes an idealized microvascular network (IMN) of one or more interconnected idealized flow channels in fluid communication through a porous wall with a tissue space (e.g., idealized tissue space). The methods of assaying the LAC can be implemented with means for quantifying modulation of the leukocyte adhesion cascade. Methods of assaying the LAC can be implemented with the device and one or more active agents to monitor leukocyte rolling, adhesion, and/or migration in the presence of absence of the active agent. Migration can be through the idealized flow channels, through the porous wall, and/or into the tissue space.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Multi-photon Tissue Imaging]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149734.html</link>
            <description><![CDATA[A multimodal method for imaging tissue comprising: aligning an excitation light source with at least a portion of the tissue; selecting at least two modalities of image acquisition; imaging the tissue portion with each of the modalities of image acquisition; and constructing a dual mode image using images from each of the modalities of image acquisition. A multimodal system for imaging tissue comprising: an excitation light source or light sources; an optical and alignment system for directing the excitation beam or beams to a sample and receiving an emission beam from the sample; at least one detector for receiving the emission beam from the sample; and a spectral filtering or dispersing device for providing at least two imaging modalities at the at least one detector; and a processor for analyzing the detected emission beam and constructing a dual mode image using images from each of the modalities of image acquisition.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[ESTABLISHMENT OF RHESUS MONKEY MODEL OF AUTOIMMUNITY TYPE 1 DIABETES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149733.html</link>
            <description><![CDATA[Use of low dose streptozocin in the preparation of an animal model for screening drugs for treatment of antoimmune type 1 diabetes is disclosed, in which streptozocin is administrated intravenously at a dose of 15-30 mg/kg per time for 5 days and administrated again on the 7th day and 14th day after last time of offering drug. A method for preparing rhesus monkey model of autoimmune type 1 diabetes and autoimmune type 1 diabetes animal model obtained are also disclosed.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD OF LABELING SULFENIC ACID-CONTAINING PROTEINS AND PEPTIDES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149732.html</link>
            <description><![CDATA[A method of labeling a sulfenic acid (—SOH) group of a cysteine residue in a protein; or peptide, comprises contacting said protein or peptide with a beta-ketoester to covalently couple said beta-ketoester to said cysteine residue and form a beta-ketoester-labeled cysteine residue in said protein or peptide.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[APPARATUS FOR CULTURING CELL AND ANALYZING CELL REACTION, AND METHOD OF ANALYZING CELL REACTION USING THE SAME]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149731.html</link>
            <description><![CDATA[Provided is an apparatus for culturing a cell and analyzing a cell reaction. The apparatus may include a plurality of cell culturing rooms, cell injection ports connected to the cell culturing rooms through cell injection channels, respectively, and used for injecting different cells from each other into the cell culturing rooms, the number of the cell injection ports being the same as that of the cell culturing rooms, and a reagent injection port to inject a reagent into the cell culturing rooms.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[EMULSION-DERIVED PARTICLES]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149730.html</link>
            <description><![CDATA[An emulsion-derived particle comprises a lattice of polymeric strands cross-linked by means of a cross-linking agent, and interstitial openings adjacent and around the strands. Functional groups are provided on the lattice and proteins and/or modified proteins can react with these, thereby to be bonded to the lattice and hence immobilised.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149729.html</link>
            <description><![CDATA[Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Oral Fluid Sample Collection Device With Indicator and Method]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149728.html</link>
            <description><![CDATA[Provided are methods and devices used for determining the presence or absence of a contaminant in the sample of oral fluid. The method involves contacting a substrate having a detectable reporter with a sample of oral fluid and, based on determining a signal from the detectable reporter determining the presence or absence of a contaminant in the sample of oral fluid. The invention is useful for detecting lactose, milk, colostrum, blood, hemoglobin, whole cells, and combinations thereof. The method can be used for detecting oral contaminants in oral fluid samples obtained from any mammal, including neonatal ungulates.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR ISOLATING UREA WHILE REMOVING OBJECTIONABLE CO2]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149727.html</link>
            <description><![CDATA[A method for isolating urea and removing CO2 from plasma samples, comprising the following steps: a) providing a plasma sample; b) adding an acid so as to partially remove CO2; c) lyophilizing the sample so as to further remove CO2 and obtain a dried sample; and d) redissolving the dried sample and neutralizing to a pH value of 4 to 7 using a buffer solution, wherein optionally a filtration step is carried out before adding the acid.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[POTENCY TEST FOR VACCINE FORMULATIONS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149726.html</link>
            <description><![CDATA[The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS AND COMPOSITIONS FOR DIAGNOSIS OF UROSEPSIS AND URINARY TRACT INFECTION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149725.html</link>
            <description><![CDATA[The present invention is directed to methods for diagnosis of urosepsis, sepsis, and urinary tract infections (UTIs), and to methods for distinguishing between urosepsis, sepsis of other origins, and localized UTIs. In some aspects, the diagnostic methods of the invention are based on determining whether a bodily fluid sample, such as urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range. The present invention also provides diagnostic kits.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[SYSTEMS, DEVICES AND METHODS FOR MICROFLUIDIC CULTURING, MANIPULATION AND ANALYSIS OF TISSUES AND CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149724.html</link>
            <description><![CDATA[Microfluidic devices for dissociating tissue, culturing, separating, manipulating, and assaying cells and methods for using the device are disclosed. Individual modules for tissue dissociation, cell, protein and particle separation, cell adhesion to functionalized, permissive micro- and nano-substrates, cell culturing, cell manipulation, cell and extracellular component assaying via metabolic and therapeutic compounds, compound titration, cell transfection, and micro-ELISA are described. Specialized micro- and nano-substrates and their methods of fabrication are also described. An integrated device is also disclosed. The devices and methods can be used for diagnostic applications, monitoring of disease progression, analysis of disease recurrence, compound discovery, compound validation, drug efficacy screening, and cell-based assays.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Method of controlling insect pests in cotton]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149723.html</link>
            <description><![CDATA[An assay system is provided in which gossypol is used as a biological marker to detect evolved resistance of insects to Bt cotton. Detection of gossypol using a monoclonal antibody ELISA-based protocol enables at risk populations of insects to be evaluated for evolved resistance to Bt present in a genetically modified cotton. The specificity of the monoclonal antibody to gossypol also enables the production of nanoparticles having a conjugated monoclonal antibody which retains the ability to selectively bind gossypol. Accordingly, nanoparticles can be provided with additional target ligands, such as antibodies, so as to specifically attach to tumors or cancer cells thereby delivering the gossypol to the target cells.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[System and Method for Quantifying Fragile X Mental Retardiation 1 Protein in Tissue and Blood Samples]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149722.html</link>
            <description><![CDATA[A system and method for the detection and quantification of fragile X mental retardation protein (FMRP) in human tissue and blood samples. The system includes several high avidity monoclonal antibodies that may be provided on Xmap microspheres to capture FMRP from a tissue or blood specimen. The resulting complex is reacted with a polyclonal anti-FMRP rabbit antibody and then mixed with an anti-rabbit IgG antibody conjugated to phycoerythrin. Fluorescence emitted from the resulting complex is a function of the amount of FMRP present in the specimen.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149721.html</link>
            <description><![CDATA[Compositions and uses of mGluR5 antagonists for the treatment and inhibition of amyloid precursor protein (APP), Aβ protein, and APP proteolytic products in Alzheimer's disease, Fragile X Syndrome, autism, and Down's Syndrome are provided. The invention provides methods for diagnosing Fragile X Syndrome via the assessment of Aβ1-42 levels in blood plasma.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[DETECTION OF SOLUBLE ADIPONECTIN RECEPTOR PEPTIDES AND USE IN DIAGNOSIS AND THERAPEUTICS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149720.html</link>
            <description><![CDATA[The present invention relates to soluble C-terminal fragments of the adiponectin receptor and their use in the diagnosis and management of disorders.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149719.html</link>
            <description><![CDATA[The present invention is directed to proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS OF DETERMINING CELLULAR CHEMOSENSITIVITY]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149718.html</link>
            <description><![CDATA[The present invention provides methods of determining cell sensitivity to a therapeutic agent.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS AND COMPOSITIONS RELATED TO DOPAMINERGIC NEURONAL CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149717.html</link>
            <description><![CDATA[A method of differentiation stem cells cells by contacting stem cells with a dopaminergic differentiation agent is provided in certain aspects. For example, the agent may comprise substituted benzoxazole. These methods and compositions may be used in toxicological screens, e.g., to evaluate the neurotoxicity of a test compound or treatment of neurological disorders.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149716.html</link>
            <description><![CDATA[Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[G-PROTEIN-CONJUGATED RECEPTOR HAVING ALTERED LIGAND AFFINITY, AND USE THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149715.html</link>
            <description><![CDATA[A modified G-protein-coupled receptor (GPCR), having modified ligand affinity is provided by binding a G-protein-coupled receptor to a polypeptide consisting of an amino acid sequence of SEQ ID NO: 1. Furthermore, agonists for or antagonists against the modified GPCR are screened using a transformant in which the modified GPCR has been expressed. This makes it possible to provide a technique for analyzing the function of many putative GPCRs whose entities have not been clarified.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[BIO-DIAGNOSTIC TESTING SYSTEM AND METHODS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149714.html</link>
            <description><![CDATA[An implantable diagnostic device in accordance with the present disclosure includes a probe assembly that can be implemented in a variety of ways. A few example implementations include: a needle inside which is located a bio-sensor chip (the needle being insertable into a human being); a compact package containing the bio-sensor chip (the compact package configured for placement inside a catheter); or a silicon-based bio-sensor package configured for insertion into a vein.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[BIOMARKERS OF HEMORRHAGIC SHOCK]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149713.html</link>
            <description><![CDATA[Methods for the use of keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) (KC/GRO), apolipoprotein A2 (APOA2), angiotensinogen r (AGT), thyroglobulin (TG), disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), anionic trypsin-1 (PRSS1), complement C4 (C4A), zona pellucida sperm-binding protein 1 (ZP1), neuropilin-2 (NRP2), solute carrier family 13 member 2 (SLC13A2), glucagon-like peptide 2 receptor (GLP2R), lipoma high mobility group protein isoform I-C (HMGIC) fusion partner-like protein 4 (LHFPL4), and claudin-3 (CLDN3) as biomarkers for diagnosis and prognosis, and for monitoring the efficacy of treatment, in hemorrhagic shock (HS).]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[FOLLISTATIN-LIKE PROTEIN-1 AS A BIOMARKER FOR INFLAMMATORY DISORDERS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149712.html</link>
            <description><![CDATA[The present invention relates to methods and compositions for diagnosis of inflammatory disorders, and in non-limiting embodiments, of inflammatory disorders associated with elevated interleukin-1β (“IL-1β”), based on increased levels of follistatin-like protein 1 (“FSTL-1”). In particular non-limiting embodiments, the invention further provides for methods of identifying subjects with systemic onset juvenile idiopathic arthritis (“SOJIA”) who are at increased risk for developing macrophage activation syndrome (“MAS”) comprising detecting, in said subjects, hyper-increased levels of FSTL-1. In additional non-limiting embodiments, the invention provides for methods of identifying subjects with Kawasaki disease who are at increased risk of developing aortic aneurysms comprising detecting, in said subjects, hyper-increased levels of FSTL-1.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[BARD1 Isoforms in Lung and Colorectal Cancer and Use Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149711.html</link>
            <description><![CDATA[The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MICRODROPLET-MANIPULATION SYSTEMS AND METHODS FOR AUTOMATED EXECUTION OF MOLECULAR BIOLOGICAL PROTOCOLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149710.html</link>
            <description><![CDATA[Disclosed herein are automated systems for performing various biochemical and molecular biological procedures, including processor-controlled execution of protocols involving multiple steps performed in, on, or with liquid microdroplets. Example protocols are the various Polymerase Chain Reaction (PCR) protocols, but the subject systems are not limited to performing PCR protocols. Formation of a microdroplet of the sample for use in the described systems is achieved by bringing an amount of the sample into contact with a hydrophobic milieu, such as a superhydrophobic surface or hydrophobic liquid.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[SOLID GEL AMPLIFICATION METHOD AND APPARATUS FOR GENOTYPING AND PATHOGEN DETECTION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149709.html</link>
            <description><![CDATA[The present invention provides for a novel system and method for amplification and detection of nucleic acids within a miniaturized device.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Multiplex PCR for Identification of B. anthracis and Detection of Plasmid Presence]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149708.html</link>
            <description><![CDATA[The present invention includes embodiments of methods and compositions related to detection or verification of the presence or absence of Bacillus anthracis in a sample. The method embodiments include assays for the presence or absence of the pXO1 and/or pXO2 plasmids, in addition to a species-specific (such as chromosomal) marker and preferably a positive internal control.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Method For Molecular Genealogical Research]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149707.html</link>
            <description><![CDATA[A genealogical research and record keeping system and method for identifying commonalities in haplotypes and other genetic characteristics of a biological sample of two or more individual members. Chromosomal fragments identical by descent identify family ties between siblings, parents and children and ancestors and progeny across many generations. It is particularly useful in corroborating and improving the accuracy of genealogical data and identifying previously unknown genetic relationships.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[OPTICAL REPORTER COMPOSITIONS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149706.html</link>
            <description><![CDATA[This invention provides compositions that have a light emitting reporter linked to biomolecules, preferably, nucleotide oligomers. The light reporter particles are silylated and functionalized to produce a coated light reporter particle, prior to covalently linking the biomolecules to the light reporter particle. The light reporter particles of the invention can be excited by a light excitation source such as UV or IR light, and when the biomolecule is DNA, the attached DNA molecule(s) are detectable by amplification techniques such as PCR.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS AND KITS FOR ROOM TEMPERATURE IN SITU DETECTION OF A TARGET NUCLEIC ACID IN A BIOLOGICAL SAMPLE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149705.html</link>
            <description><![CDATA[The present invention relates to in situ hybridization methods for detecting a target nucleic acid in a biological sample comprising performing one or more method steps (e.g., pretreatment, denaturation, hybridization, washes) at room temperature. The invention further relates to kits for performing such methods.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MATERIALS AND METHODS FOR DIAGNOSIS OF MALIGNANT MELANOMA AND PROGNOSIS OF METASTASIS OF MALIGNANT MELANOMA]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149704.html</link>
            <description><![CDATA[Methods, probes and kits for diagnosing malignant melanoma and prognosing metastasis thereof in a patient.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA["MARKERS FOR PROSTATE CANCER PROGRESSION"]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149703.html</link>
            <description><![CDATA[Purpose. The relationship between inherited genetic variations in 5α-reductase type 1 (SRD5A1) and type 2 (SRD5A2) genes and the risk of biochemical recurrence after radical prostatectomy (RP) in prostate cancer (PCa) remains a fairly unexplored area of research. Patients and Methods. We studied 526 men with organ-confined and locally advanced PCa with a median follow-up time of 7.4 years. We investigated the effects of allelic variants of SRD5A1 and SRD5A2 genes and haplotype-tagging single nucleotide polymorphisms (htSNPs; n=19) on recurrence-free survival after RP using Kaplan-Meier plots, the log-rank test, and Cox proportional hazard models. Results. Upon adjusting for known prognostic clinical and pathological factors, eight htSNPs were shown to be independent predictors of recurrence. The SRD5A1 rs166050 polymorphism was associated with an increased recurrence risk of HR=1.83 (95% CI, 1.04-3.21; P=0.035), while the rs518673 in SRD5A1 was associated with a decreased risk (HR=0.59, 95% CI, 0.41-0.85; P=0.004). The SRD5A2 gene was strongly associated with the risk of relapse with six polymorphisms being positively associated with recurrence including the known SRD5A2 V89L (rs523349) (HR=2.14, 95% CI, 1.23-3.70; P=0.007) and a protective htSNP rs12470143 with a HR of 0.66, (95% CI, 0.46-0.95; P=0.023). By combining SRD5A1 (rs518673T) and SRD5A2 (rs12470143 A), the protective effect was shown to be additive with the maximum protection conferred by 3 or 4 alleles (HR=0.33, 95% CL 0.17-0.63; P=0.001). Conclusion. Germline polymorphisms in 5α-reductase genes are independent prognostic genetic biomarkers that predict PCa biochemical recurrence after radical prostatectomy and may represent useful molecular tools for a genotype-tailored clinical approach.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PRIMER SET, METHOD AND KIT FOR DETECTING PATHOGEN IN FISH]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149702.html</link>
            <description><![CDATA[The invention provides a method for rapidly detecting a pathogen in fish comprising conducting loop-mediated isothermal amplification with a specific primer set and a nucleic acid in a test sample. If at least one amplification is carried out, the test sample comprises the pathogen in fish. The invention also provides a primer set, probe and kit for detecting a pathogen in fish.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS OF IDENTIFYING THERAPEUTIC AGENTS FOR TREATING PERSISTER AND BACTERIAL INFECTION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149701.html</link>
            <description><![CDATA[The present invention relates to methods, compositions, assays and kits for identifying an antibacterial agent that decreases persister formation or survival, eliminates or reduces bacterial infection or disease and/or increases killing of a bacterial cell.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MEASUREMENT OF AUTOANTIBODIES AT LOW CONDUCTIVITY WITH INCREASED SENSITIVITY]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149700.html</link>
            <description><![CDATA[Methods for detecting or capturing low-avidity autoantibodies in a biological sample are provided. Target antigen used to assay for the low-avidity autoantibodies of interest is immobilized on a solid phase. The biological sample is contacted under low conductivity condition with the target antigen for which the autoantibodies has specific binding affinity. Binding of the target antigen to the autoantibodies of interest in the biological sample is then detected to ascertain the presence or concentration of the autoantibodies of interest.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Translation Kinetic Mapping, Modification and Harmonization]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149699.html</link>
            <description><![CDATA[The profile of translation elongation rate along an mRNA is modulated in a directed manner by locally altering codon usage, in particular utilizing differences in ribosomal dwell times among pairs of synonymous codons translated by a single tRNA through wobble base pairing. Unlike codon optimization based on organism-specific codon frequencies or tRNA pools, the methods of the invention need not change the tRNA that translates the codon, rather modulating the interaction between a given tRNA and the mRNA coding sequence.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[STABLE COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION AND SEQUENCING]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149698.html</link>
            <description><![CDATA[The present invention is directed to compositions comprising mixtures of reagents, including thermostable enzymes (e.g., thermostable DNA polymerases), buffers, cofactors and other components, suitable for immediate use in nucleic acid amplification or sequencing techniques without dilution or addition of further components. The compositions contain no stablizing agents (e.g., glycerol or serum albumin) and unexpectedly maintain activity for extended periods of time upon storage at temperatures above freezing. These compositions are useful, alone or in the form of kits, for nucleic acid amplification (e.g., by the Polymerase Chain Reaction) and sequencing (e.g., by dideoxy or “Sanger” sequencing), or for any procedure utilizing thermostable DNA polymerases in a variety of medical, forensic and agricultural applications. In particular, the compositions and methods are useful for amplifying and sequencing nucleic acid molecules that are larger than about 7 kilobases in size.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[DETECTION OF HPV]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149697.html</link>
            <description><![CDATA[The present invention provides compositions and methods for the detection and characterization of HPV sequences. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of HPV sequences. The present invention also provides compositions, methods and kits for screening sets of HPV sequences in a single reaction container.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[HIGH-THROUGHPUT METHOD FOR DETERMINING THE PRESENCE OF PAPILLOMAVIRUS-NEUTRALIZING ANTIBODIES IN A SAMPLE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149696.html</link>
            <description><![CDATA[The present invention relates to a method for the determination of the presence of PV-neutralizing antibodies in a sample, comprising a) contacting said sample with infectious PV particles comprising a reporter gene, wherein the gene product of said reporter gene is secreted into the growth medium, b) contacting the PV particles from a) with host cells, and c) determining PV-neutralizing antibodies based on the amount of gene product from said reporter gene, wherein, preferably, a lower amount of said gene product as compared to a reference amount is indicative of the presence of PV-neutralizing antibodies. It further relates to a host cell strongly adhering to multi-cluster plates for use in a method for diagnosing anti-PV immunity comprising the method of the present invention.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR DETECTING GENETIC MUTATION BY USING A BLOCKING PRIMER]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149695.html</link>
            <description><![CDATA[The present invention provides a method for detecting a gene mutation, comprising the step of performing PCR using generic PCR primers together with a blocking primer which competes with the generic primers and was modified at one end, and a method of diagnosing gene mutation-related diseases using the same. According to the invention, detection sensitivity and specificity can be increased by blocking the amplification of normal DNA and selectively amplifying mutant DNA.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS, DEVICES, KITS AND COMPOSITIONS FOR DETECTING ROUNDWORM, WHIPWORM, AND HOOKWORM]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149694.html</link>
            <description><![CDATA[Methods, devices, kits and compositions for detecting the presence or absence of one or more helminthic coproantigens in a sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm, whipworm and/or hookworm in a fecal sample from a mammal and may also be able to distinguish between one or more helminth infections. Confirmation of the presence or absence of roundworm, whipworm and/or hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MANAGEMENT OF ETHANOL CONCENTRATION DURING SYNGAS FERMENTATION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149693.html</link>
            <description><![CDATA[A process is provided for management of ethanol concentration during syngas fermentation. A process for fermentation of syngas includes inoculating a medium to provide an inoculated medium. Inoculated medium is contacted with syngas and cells and medium are removed and separated to provide concentrated cells and permeate. Ethanol is separated from the permeate to provide ethanol and a reduced ethanol aqueous stream. The reduced ethanol aqueous stream is returned to the fermentation.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods And Apparatus For Donor Platelet Pre-Count In Centrifugal Blood Separator]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149692.html</link>
            <description><![CDATA[A method for determining platelet pre-count in centrifugal blood processing apparatus comprising a centrifuge rotor, a separation chamber, a tubing set for conducting blood components and fluids and having an inlet line, and an outlet line. The apparatus tests flow conditions using a red light-green light sensor to determine a donor platelet pre-count.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods, Reagents and Kits for Preservation of Nucleic Acids in Biological Samples]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149691.html</link>
            <description><![CDATA[Provided is a nucleic acid preservative comprising at least one reducing agent, at least one chaotropic substance, at least one polyamine substance and at least one chelating agent and uses thereof, and a method for the preservation of nucleic acids in a biological sample. Further provided are kits for use in the preservation of nucleic acids in a biological sample, and more particularly, a blood sample.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[TUNED MULTIFUNCTIONAL MAGNETIC NANOPARTICLES FOR BIOMEDICINE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149539.html</link>
            <description><![CDATA[Magnetic nanoparticles and related devices and methods are described. Compositions and methods can include magnetic nanoparticles having a narrow size distribution for use in diagnostics and therapeutics.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Natural Nonwoven Materials]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149512.html</link>
            <description><![CDATA[There is described a nonwoven material comprising a multilayered stack, the multilayered stack comprising discrete interconnected layers, each of the layers, which may be the same or different, comprising a composite fibre of from about 80 to 100% w/w leaf or stem fibre and from about 1 to 20% w/w of a polymer, wherein the polymer is fusible at a temperature of about 180° C. or less. There is also described a novel method of enzyme degumming leaf and/or stem fibres.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[LETTUCE VARIETY 45-89 RZ, "CALEDONAS"]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149426.html</link>
            <description><![CDATA[The present invention relates to a Lactuca sativa seed designated 45-89 RZ, which exhibits a combination of traits including resistance to downy mildew (Bremia lactucae Regel.) races NL:1-16 and Bl:18-28, and resistance to currant-lettuce aphid (Nasonovia ribisnigri) biotype Nr:0. The present invention also relates to a Lactuca sativa plant produced by growing the 45-89 RZ seed. The invention further relates to methods for producing the lettuce cultivar, represented by lettuce variety 45-89 RZ.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Use of manganese for enhancing the growth of L.casei in mixed cultures.]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149415.html</link>
            <description><![CDATA[The invention relates to a method for selectively enhancing the growth of bacteria from the Lactobacillus casei group in a mixed culture, by adding manganese to the culture medium. Said method is suitable in particular in the case of mixed cultures associating Lactobacillus casei with yogurt bacteria.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS AND METHOD FOR OPTIMIZING PRODUCTION OF FOOD AND FEED]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149411.html</link>
            <description><![CDATA[A process includes microbially degrading harvested polyculture plant material to form a concentrated microbial biomass and providing the concentrated microbial biomass to an intermediary animal for consumption. The process may also be directed to producing a product animal which includes providing a growth area having an outlet for waste and providing a harvested plant material collection area having an outlet for degradation products. The process may also include providing a microbial growth system for producing a bacterial biomass and directing at least some waste from the outlet of the product animal growth area to the harvested plant material collection area. The process may also include directing at least some degradation products to the microbial growth system, directing some of the microbial biomass produced in the microbial growth system to an intermediary animal for consumption, and directing the intermediary animal to a product animal growth area.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Modulation of Thymosin Beta-4 in Skin]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149397.html</link>
            <description><![CDATA[Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents, other than a retinoid, that stimulate thymosin beta-4 expression in the skin. Also provided are methods for screening for substances which stimulate thymosin beta-4 expression levels and the methods of using active agents identified by the screening protocol in the treatment of skin.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[BIOMARKERS OF LUNG FUNCTION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149389.html</link>
            <description><![CDATA[Cigarette smoking is a primary determinant of chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of morbidity and mortality in the United States. Unique proteins associated with COPD capable of differentiating subjects likely to experience rapid (RPD) or slow (SLW) decline in lung function have been identified using comprehensive high-throughput proteomic approaches. Thirty peptides, which mapped to 21 unique proteins, were linearly associated with annualized rates of lung function decline among smokers with COPD characterized as having rapid or slow decline and smokers without COPD. Using three different statistical approaches to assess the data, the RPD and SLW groups are differentiated by 55 peptides, which mapped to 33 unique proteins. A number of the identified peptides are proteolytic fragments of proteins that are involved in the complement and/or coagulation systems, have anti-protease activity, or metabolic functions.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[CD36 AS BIOMARKER FOR STEATOSIS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149386.html</link>
            <description><![CDATA[A method is provided for early treatment of steatosis, which method is based on early detection of steatosis based on the detection of CD36. CD36 is determined in a body fluid, and CD36 levels above a predetermined value is indicative of steatosis.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Compositions, methods and kits for modeling, diagnosing, and treating complement disorders]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149373.html</link>
            <description><![CDATA[Systems, compositions, methods, and kits for identifying potential therapeutic agents for treatment of complement based ocular diseases are provided herein. The methods and kits include a complement component 3 (C3) protein or derivative that is contacted to ocular cells or tissue. Another embodiment of the invention herein provides for diagnosis and/or prognosis of a complement-associated ocular disease. Compositions, methods and kits for regulating or treating a complement-related condition using at least one of CD46 protein, CD55 protein, and a recombinant chimeric soluble terminator of activated complement (STAC) protein or source of the STAC protein. The STAC protein includes an amino acid sequence including at least two of an amino acid sequence of a CD59 protein, an amino acid sequence derived from a CD46 protein, and an amino acid sequence derived from a CD55 protein, optionally further comprising a linker to connect amino acid sequences.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Polypeptides for the Treatment or Prevention of Cancer and uses Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149372.html</link>
            <description><![CDATA[Disclosed herein are polypeptides or their derivatives and their application. The polypeptides and their derivatives can treat or prevent cancer. The polypeptides of the invention have significant lethality to the cancer cells when used alone. When its clinical commonly used chemotherapy drugs such as cisplatin in combination, it can significantly increase the sensitivity of chemotherapeutic agents on cancer cells, to enhance its lethality of cancer cells, to reduce the dosage. The peptides can kill a variety of cancer cells, but without apparent toxicity enhancing effect on normal cells. The prepared peptides of the present invention can be chemically synthesized, high-purity, low molecular weight, specificity, non-immunogenic, safe and reliable.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITION FOR NUCLEIC ACID TRANSFECTION]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149369.html</link>
            <description><![CDATA[The invention provides a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates an effective nucleic acid transfection into a cell, and which improves expression of the nucleic acid in the cell. The composition for transfecting a nucleic acid into a cell, contains a di(C12-16 alkyl)dimethylammonium halide and a phospholipid.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[POLYMER SCAFFOLDS AND THEIR USE IN THE TREATMENT OF VISION LOSS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149351.html</link>
            <description><![CDATA[The present invention provides for scaffolds for growing RPE cells, comprising two or more biodegradable polymers. The present invention also provides for methods for creating a scaffold for growing RPE cells. Additionally, the present invention provides for RGD peptide linked polymer scaffolds for supporting the growth of RPE cells. The present invention provides methods of culturing RPE cells using the scaffolds produced herein. The present invention also provides methods of treating vision loss through the administration of RPE cell attached RGD peptide linked polymer scaffolds produced herein. The present invention further provides kits for treating vision loss.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[USE OF COMPOUNDS WITH THROMBOPOIETIC ACTIVITY TO PROMOTE BONE GROWTH AND HEALING]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149349.html</link>
            <description><![CDATA[TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[ISOLATED RENAL CELLS AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149347.html</link>
            <description><![CDATA[The invention is directed to isolated renal cells, including tubular and erythropoietin (EPO)-producing kidney cell populations, and methods of isolating and culturing the same, as well as methods of treating a subject in need with the cell populations.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITION COMPRISING PROBIOTIC BACTERIA FOR USE IN THE TREATMENT OF IMMUNE DISORDERS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149342.html</link>
            <description><![CDATA[The present invention relates to a composition comprising probiotic bacteria for the treatment of pathologies associated with alterations of the immune system. In particular, the present invention relates to the use of selected probiotic bacteria for the preparation of a composition for the treatment of allergies, such as atopic dermatitis.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149339.html</link>
            <description><![CDATA[It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149336.html</link>
            <description><![CDATA[The invention is directed to methods of screening immunogenic viral like particles and related immunogenic compositions and diagnostic techniques. In one embodiment, the invention provides methods of screening immunogenic viral like particles containing peptides corresponding to epitope regions of a wide variety of pathogens, including viruses, bacteria, parasites, and microbes. Non-infectious antigens and allergens of interest can also be screened as described herein. Immunization, therapeutic and diagnostic applications are also described for the compositions and methods according to the invention. In another embodiment, the invention provides novel methods of identifying a cryptic neutralizing epitope and related vaccines, constructs, and libraries. In some embodiments, these methods use high-throughput formats that are facilitated by in silica or in vitro steps.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149334.html</link>
            <description><![CDATA[The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PHARMACEUTICAL PRODUCTS FROM FUNGAL STRAINS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149333.html</link>
            <description><![CDATA[Disclosed herein are compositions comprising an isolated cellulose degrading fungus and pharmaceutical substances produced by the fungus.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[RHAMNOSE AND FORSSMAN CONJUGATED IMMUNOGENIC AGENTS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149331.html</link>
            <description><![CDATA[The present invention provides an immunogenic composition comprising a T-cell antigen in association with a rhamnose monosaccharide and/or Forssman disaccharide, and corresponding methods for inducing immune response. The T-cell antigen may be for example, a tumor vaccine, such as a tumor cell or one or more tumor antigens. The invention takes advantage of the naturally high titers of anti-Rhamnose and/or anti-Forssman disaccharide in humans to target vaccine compositions to antigen presenting cells.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MUTATED LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149323.html</link>
            <description><![CDATA[A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PROCESS FOR EXTRACTING MATERIALS FROM BIOLOGICAL MATERIAL]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149322.html</link>
            <description><![CDATA[The invention is directed to a process for extracting materials from biological material, which process is characterized in that the naturally occurring biological material is treated with an extractant consisting of a deep eutectic solvent of natural origin or a an ionic liquid of natural origin to produce a biological extract of natural origin dissolved in the said solvent or ionic liquid.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Asf1b as a Prognosis Marker and Therapeutic Target in Human Cancer]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149320.html</link>
            <description><![CDATA[The present invention provides a prognostic marker in human cancer, Asf1b, a high expression thereof being associated with a poor prognosis. The present invention also provides a method for selecting a subject affected with a cancer for an adjuvant therapy. Finally, the present invention provides a new therapeutic target for treating cancer.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149316.html</link>
            <description><![CDATA[The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[ANTIBODIES AGAINST GLUCAGON RECEPTOR AND THEIR USE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149315.html</link>
            <description><![CDATA[Disclosed are immunological compositions and methods for reducing activity of glucagon signaling using antibodies against glucagon receptor.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[p19Arf, HMGA2 and MDM2 For Use in the Diagnosis and Treatment of Aberrant Cell Growth]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149314.html</link>
            <description><![CDATA[Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying anti-tumor agents are described. Furthermore, novel methods and compositions are provided for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and their descendants and for the treatment of obesity are disclosed.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149313.html</link>
            <description><![CDATA[The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid β and advanced glycation-end-products.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[GFI1B MODULATION AND USES THEREOF]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149311.html</link>
            <description><![CDATA[Methods, uses and kits for increasing the number of hematopoietic stem cells (HSCs) in a biological system, such as for increasing the number of HSCs in the bone marrow and/or blood of a subject, based on the modulation of growth factor independence 1b (Gfi1b), are disclosed.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[NOVEL REGULATORY PROTEINS AND INHIBITORS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149309.html</link>
            <description><![CDATA[The invention provides a previously uncharacterized protein (gamma secretase activating protein or gSAP) that activates γ-secretase to produce β-amyloid protein (Aβ). Deposition of Aβ has been associated with Alzheimer's disease and other pathologies. The invention thus additionally provides, e.g., screening methods and novel research tools, inhibitors of this novel protein, and methods of diagnosis, treatment and control of Alzheimer's disease and other neurodegenerative conditions associated with deposition of Aβ.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[ANTIBODIES TO IL-1BETA AND IL-18, FOR TREATMENT OF DISEASE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149308.html</link>
            <description><![CDATA[The present invention relates to compositions and methods for treatment of disease. More particularly, the present invention relates to anti-IL-1β and anti-IL-18 antibodies, including anti-IL-1β and anti-IL-18 bispecific antibodies, and methods of treating disease using such antibodies.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149306.html</link>
            <description><![CDATA[The present invention is related to the treatment of certain cancers using antagonists of the binding between a Plexin and a Sema3E. The invention may be helpful in treating primary cancer cell development and metastasis development wherein Sema3E is expressed, in particular overexpressed by the tumoral cells or the stroma. Breast cancer, in particular with distant metastases is concerned. Prostate cancer, melanoma and glioblastoma are also concerned. The antagonist may be any molecule that specifically binds to PlexinD1 or Sema3E and blocks the Sema3E/PlexinD1 binding. In an embodiment, the antagonist is a polypeptide or an antibody.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[SOLUBLE CD80 AS A THERAPEUTIC TO REVERSE IMMUNE SUPRESSION IN CANCER PATIENTS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149305.html</link>
            <description><![CDATA[The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDLL and inhibits PDLL-PD1 interactions thereby overcoming PDLL-induced immune suppression and restoring T cell activation.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[USE OF MODULATORS OF COMPOUNDS OF TGF-BETA SUPERFAMILY TO REGULATE HEPCIDIN-MEDIATED IRON METABOLISM]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149304.html</link>
            <description><![CDATA[The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[MONOCLONAL ANTIBODIES WITH ALTERED AFFINITIES FOR HUMAN FCyRI, FCyRIIIa, AND C1q PROTEINS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149300.html</link>
            <description><![CDATA[Disclosed herein are GNGN and G1/G2 antibodies that recognize and bind various FcRs and C1q. Also disclosed herein are glycan-optiminzed antibodies, predominantly of the GNGN or G1/G2 glycoform, with enhanced Fcγ receptor binding achieved through CHO, Nicotiana benthamiana and yeast manufacturing systems. Nucleic acids encoding these antibodies, as well as expression vectors and host cells including these nucleic acids are also disclosed herein. Methods and pharmaceutical compositions including the monoclonal antibodies are provided herein for the prevention and/or therapeutic treatment of viral infections, cancers and inflammatory diseases.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[ROLE OF FRAGILE X MENTAL RETARDATION GENE AND PROTEIN IN CANCER METASTASIS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149297.html</link>
            <description><![CDATA[The present application relates to the field of cancer. Surprisingly, it was shown that the Fragile X mental retardation gene (Fmr1) products such as the FMRP protein, primarily implicated in mental retardation, are upregulated in metastasizing tumours. It is shown how Fmr1 gene products can be used as a marker for cancer metastasis and how inhibition of these gene products may help prevent or reduce metastasis.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[PRODUCTION AND USE OF BACTERIAL HISTAMINE]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149291.html</link>
            <description><![CDATA[A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an. active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production, of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Engineered Dendritic Cells and Uses for the Treatment of Cancer]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149290.html</link>
            <description><![CDATA[This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[T CELL RECEPTOR MUTANTS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149289.html</link>
            <description><![CDATA[A T cell receptor (TCR) having the property of binding to EVDPIGHLY HLA-A1 complex and comprising a specified wild type TCR which has specific mutations in the TCR alpha variable domain and/or the TCR beta variable domain to increase affinity. Such TCRs are useful for adoptive therapy.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS OF GENERATING OLIGODENDROCYTES AND CELL POPULATIONS COMPRISING SAME]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149288.html</link>
            <description><![CDATA[A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Corticogenesis of Human Pluripotent Cells]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149287.html</link>
            <description><![CDATA[This invention relates to in vitro methods for the induction of corticogenesis in human pluripotent cells, such as iPS cells, by culturing the cells under conditions which stimulate retinoid signalling and inhibit TGFβ superfamily signalling. This may be useful in production of cortical neurons, in particular patient-specific cortical neurons; the modelling of juvenile and adult-onset neurological diseases; and the development of therapeutics.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS FOR OBTAINING STEM CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149286.html</link>
            <description><![CDATA[The present invention relates to methods for obtaining stem cells from mammalian cadavers, methods for obtaining or purifying stem cells from a sample likely to contain non-stem cells, methods of regeneration of injured tissues and methods of treatment.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149284.html</link>
            <description><![CDATA[The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149283.html</link>
            <description><![CDATA[A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[OPTICAL SENSOR CONJUGATES FOR DETECTING REACTIVE OXYGEN AND/OR REACTIVE NITROGEN SPECIES IN VIVO]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149251.html</link>
            <description><![CDATA[The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[HYPERPOLARIZED AGENTS FOR MRI CHARACTERIZATION OF REDOX SYSTEMS IN VIVO]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149250.html</link>
            <description><![CDATA[The present invention provides a MRI probe of use in detecting and characterizing redox systems in vivo. Also provided are methods of using the probe in MR imaging experiments for diagnosis of disease in a subject, for drug discovery and for probing the redox states of biological systems in vitro.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[VIVO TUMOR TARGETING AND SPECTROSCOPIC DETECTION WITH SURFACE-ENHANCED RAMAN NANOPARTICLE TAGS]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149247.html</link>
            <description><![CDATA[Nanostructures, methods of preparing nanostructures, methods of detecting targets in subjects, and methods of treating diseases in subjects, are disclosed. An embodiment, among others, of the nanostructure includes a metallic gold surface-enhanced Raman scattering nanoparticle, a Raman reporter and a protection structure. The protection structure may include a thiol-polyethylene glycol to which may be attached a target-specific probe.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Human Monoclonal Antibodies Against Hendra and Nipah Viruses]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149246.html</link>
            <description><![CDATA[The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Novel Peptides and Uses Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149245.html</link>
            <description><![CDATA[The invention relates to a peptide of 8-50 amino acids comprising the sequence of KAHKKRAD or KARKKHAD, or a cyclic peptide of 8-50 amino acids comprising the sequence of HKKR or RKKH. Also disclosed are methods of using the peptide for detecting, monitoring, or treating cancer.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0149236.html</link>
            <description><![CDATA[The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[3,5,3'-Triiodothyronine Sulfate As Thyromimetic Agent And Pharmaceutical Formulations Thereof]]></title>
            <link>http://www.freepatentsonline.com/y2013/0146502.html</link>
            <description><![CDATA[The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations for oral administration thereof.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
        <item>
            <title><![CDATA[METHOD FOR PROCESSING A LIGNOCELLULOSIC BIOMASS MATERIAL]]></title>
            <link>http://www.freepatentsonline.com/y2013/0145682.html</link>
            <description><![CDATA[Method for processing a lignocellulosic biomass material, comprising (a) a pretreatment process, in which the biomass is prepared for enzymatic hydrolysis, and (b) a subsequent hydrolysis process, in which the pretreated biomass is subjected to enzymatic hydrolysis of its cellulosic components to convert them into sugars, wherein the pretreatment process (a) is carried out in the presence of a tertiary polyamide additive. The additive may be used to improve the efficiency of the hydrolysis process (b). Also provided are processes for the production of a fermentation product from lignocellulosic biomass, and/or for the production of a biofuel or biofuel component.]]></description>
            <pubDate>Thu, 13 Jun 2013 08:00:00 EDT</pubDate>
        </item>
    </channel>
</rss>